Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Humana Inc For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Align Technology

A. O. Smith

Centene

Elevance Health Inc

Enphase Energy

Erie Indemnity

First Solar

Genuine Parts

Mohawk Industries

Moderna

Qorvo

Super Micro Computer

Teradyne

Super Micro joined the list after a 33% drop on Wednesday.

These are the S&P 500's biggest laggards for October, down by as much as 29%

Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.

Humana Q3 Earnings Beat on Growing Premiums & Cost Management

Humana Inc. (NYSE:HUM ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Lisa Stoner - VP, IR James Rechtin - President and CEO Susan Diamond - CFO George Renaudin - President, Insurance Conference Call Participants Justin Lake - Wolfe Research Ann Hynes - Mizuho Andrew Mok - Barclays Ben Hendrix - RBC Capital Markets Sarah James - Cantor Fitzgerald Joshua Raskin - Nephron Research Stephen Baxter - Wells Fargo Joanna Gajuk - Bank of America George Hill - Deutsche Bank Whit Mayo - Leerink Partners A.J. Rice - UBS David Windley - Jefferies Michael Ho - Baird Operator Good day and thank you for standing by.

Humana Inc. (HUM) Q3 2024 Earnings Call Transcript

Humana (NYSE:HUM), a for-profit American health insurance firm, reported a beat on the top and bottom lines for the third quarter and strengthened its full year profit guidance, sending its shares higher on Wednesday. Revenue for Q3 was $29.3 billion, topping estimates of $28.7 billion.

Humana updates profit guidance as Q3 results top estimates

While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Humana (HUM) Q3 Earnings: A Look at Key Metrics

Humana (HUM) came out with quarterly earnings of $4.16 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $7.78 per share a year ago.

Humana (HUM) Q3 Earnings and Revenues Beat Estimates

The health insurer still sees full-year adjusted per-share earnings of at least $16.

Humana's earnings boosted as Medicare Advantage membership exceeds expectations

Humana beat Wall Street estimates for third-quarter profit on Wednesday, helped by strength in its government-backed Medicare Advantage insurance business for older adults.

Humana beats quarterly profit estimates

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended September 30, 2024 (3Q24) versus the quarter ended September 30, 2023 (3Q23) and for the nine months ended September 30, 2024 (YTD 2024) versus the nine months ended September 30, 2023 (YTD 2023) as noted in the tables below. Consolidated income before income taxes and equity in net earnings (pretax results) In millions 3Q24 (a) 3Q23 (a).

Humana Reports Third Quarter 2024 Financial Results; Updates Full Year Adjusted 2024 Financial Guidance

NEW YORK--(BUSINESS WIRE)---- $HUM #Humana--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Company”) (NYSE: HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM. Investigation Details On October 2, 2024, Humana disclosed that it has “approximately 1.6 million, or 25%, of its members currently e.

HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Humana Inc. and Encourages Investors to Contact the Firm

HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.

Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?

NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humana Inc. (HUM) and Encourages Shareholders to Learn More About the Investigation

Cigna

There has been speculation of a massive merger in the medical sector between two massive health insurers. Specifically, the rumor is The Cigna Group NYSE: CI is interested in acquiring Humana Inc. NYSE: HUM.

Cigna Considers Humana Acquisition – What It Means for the Stocks

LOS ANGELES, CA / ACCESSWIRE / October 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc. Is Being Investigated For Securities Fraud And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Evaluate the expected performance of Humana (HUM) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

What Analyst Projections for Key Metrics Reveal About Humana (HUM) Q3 Earnings

NEW YORK CITY, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM.

Humana Inc. (HUM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. (“Humana” or “the Company”) (NYSE: HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM.

HUM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Humana Inc. and Encourages Investors to Contact the Firm

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM). Investors who purchased Humana securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUM.

Bronstein, Gewirtz & Grossman, LLC Encourages Humana Inc. (HUM) Shareholders to Inquire about Securities Investigation

LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders To Join An Inquiry Into Humana Inc For Securities Law Violations

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 31, 2025 to stockholders of record as of the close of business on December 31, 2024. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the million.

Humana Board Declares Payment of Quarterly Dividend to Stockholders

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Named “Best-of-the-Best” Company for Supplier Diversity by the National LGBT Chamber of Commerce.

Humana Named “Best-of-the-Best” Company for Supplier Diversity by the National LGBT Chamber of Commerce

LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Humana Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana and Longevity Health multi-state agreement expands access to Humana Together in Health, a Medicare Advantage Institutional Special Needs Plan.

News for Humana Stock (HUM)